Opinion: With Aduhelm, history can repeat itself by following cancer’s success

The Food and Drug Administration’s approval of Biogen’s Alzheimer’s drug Aduhelm has stirred intense controversy, with pundits launching attacks on multiple fronts. Professors focus on population outcomes rather than individual treatment responses; politicians worry about drug pricing rather than disease cost; critics pounce on the FDA’s narrowing of the drug’s label to reflect its clinical trial — all casting doubt on the drug’s effectiveness and value.

What’s been lost in the flurry is an understanding of how progress against complex diseases advances — and the historic importance of Aduhelm as a first step in that process.

Read the rest…

Read Original Article: Opinion: With Aduhelm, history can repeat itself by following cancer’s success »